Novoheart files provisional US patent application on artificial intelligence for detecting cardiac effects of drug

Novoheart has filed a provisional US patent application (Serial No. 62/525,044) on a new technology co-invented by scientific co-founders Professors Ronald Li and Michelle Khine, based on the work performed as part of the Sponsored Research Agreement completed in April 2017. The invention utilizes cutting-edge machine learning technology for predicting the effects of drugs, allowing rapid and simultaneous comparison of large amounts of drug screening data obtained with the MyHeartTM Platform. A joint publication on the research work is now in press in Stem Cell Report.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!